Bank of America (NYSE: BAC) reports 6.7% holding in Fulcrum Therapeutics (FULC)

Rhea-AI Filing Summary

Bank of America Corporation, through certain wholly owned subsidiaries, reports beneficial ownership of common stock of Fulcrum Therapeutics, Inc..

The group holds 4,468,123 shares of Fulcrum Therapeutics common stock, representing 6.7% of the outstanding class, based on 66,633,321 shares outstanding as reported by Fulcrum Therapeutics in its Form 10-Q for share totals as of April 20, 2026. All reported shares are held with shared voting and shared dispositive power; Bank of America and its reporting subsidiaries have no sole voting or dispositive power over these shares. The filing is made jointly on behalf of Bank of America Corporation and its wholly owned subsidiaries BofA Securities, Inc., Bank of America N.A., and Merrill Lynch International.

Key Figures

Shares beneficially owned: 4,468,123 shares Percent of class owned: 6.7% Shares outstanding baseline: 66,633,321 shares +4 more

7 metrics

Shares beneficially owned 4,468,123 shares Beneficial ownership of Fulcrum Therapeutics common stock reported by Bank of America

Percent of class owned 6.7% Portion of Fulcrum Therapeutics common stock reported as beneficially owned

Shares outstanding baseline 66,633,321 shares Fulcrum Therapeutics shares outstanding as of April 20, 2026 per Form 10-Q

Sole voting power 0 shares Shares over which Bank of America has sole voting power

Shared voting power 4,468,123 shares Shares over which Bank of America has shared voting power

Sole dispositive power 0 shares Shares over which Bank of America has sole dispositive power

Shared dispositive power 4,468,123 shares Shares over which Bank of America has shared dispositive power

Key Terms

beneficial ownership, shared voting power, shared dispositive power, parent holding company, +2 more

6 terms

beneficial ownership financial

"The beneficial ownership calculation relies on the 66,633,321 outstanding shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

shared voting power financial

"Shared Voting Power 4,468,123.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 4,468,123.00"

parent holding company financial

"If a parent holding company has filed this schedule, pursuant to (ii)(G)"

broker dealer financial

"BofA Securities, Inc., a broker dealer registered under section 15 of the Act"

A broker-dealer is a firm or individual that helps people buy and sell stocks, bonds and other securities (acting as a broker) and may also trade those same securities with its own money (acting as a dealer). It matters to investors because broker-dealers execute trades, hold assets, provide access to markets and research, and can create conflicts of interest — like a market operator that also sells its own goods — so their costs, speed and trustworthiness directly affect investment outcomes.

non-U.S. institution financial

"Merrill Lynch International, a non-U.S. institution in accordance with section 240.13d-1"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 12:13 PM Accepted by SEC EDGAR 08/03/2026 - 12:12 PM Learn about SEC filing dates

FAQ

What percentage of Fulcrum Therapeutics (FULC) does Bank of America report owning?

Bank of America reports beneficial ownership of 6.7% of Fulcrum Therapeutics’ common stock. This is based on 4,468,123 shares held versus 66,633,321 shares outstanding as disclosed by Fulcrum in its April 27, 2026 Form 10-Q.

How many Fulcrum Therapeutics (FULC) shares does Bank of America beneficially own?

Bank of America reports beneficial ownership of 4,468,123 shares of Fulcrum Therapeutics common stock. This stake represents 6.7% of the class, calculated using 66,633,321 outstanding shares reported as of April 20, 2026.

Does Bank of America have sole or shared voting power over its FULC shares?

Bank of America reports 0 shares with sole voting power and 4,468,123 shares with shared voting power in Fulcrum Therapeutics. The same 4,468,123 shares are also held with shared dispositive power and no sole dispositive power.

Which Bank of America entities hold the reported Fulcrum Therapeutics (FULC) position?

The position is reported by Bank of America Corporation on behalf of itself and wholly owned subsidiaries BofA Securities, Inc., Bank of America N.A., and Merrill Lynch International, each classified under applicable sections of the Securities Exchange Act.

What share count did Bank of America use to calculate its 6.7% stake in FULC?

The 6.7% beneficial ownership is calculated using 66,633,321 shares outstanding, as disclosed by Fulcrum Therapeutics in its Form 10-Q filed April 27, 2026, reporting share totals as of April 20, 2026.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Fulcrum Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

359616109

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 359616109

1

Names of Reporting Persons

BANK OF AMERICA CORP /DE/

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,468,123.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,468,123.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,468,123.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.7 %

12

Type of Reporting Person (See Instructions)

HC

Comment for Type of Reporting Person: The beneficial ownership calculation relies on the 66,633,321 outstanding shares disclosed in the Form 10-Q by the issuer on April 27, 2026, which reports share totals as of April 20, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Fulcrum Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 26 LANDSDOWNE STREET, CAMBRIDGE, MASSACHUSETTS, 02139.
Item 2.
(a)	Name of person filing: BANK OF AMERICA CORP /DE/
(b)	Address or principal business office or, if none, residence: 100 N TRYON ST CHARLOTTE, NC 28255
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 359616109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4,468,123.00
(b)	Percent of class: 6.7%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0.00
	(ii) Shared power to vote or to direct the vote: 4,468,123.00
	(iii) Sole power to dispose or to direct the disposition of: 0.00
	(iv) Shared power to dispose or to direct the disposition of: 4,468,123.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. This statement on Schedule 13G is being filed by Bank of America Corporation on behalf of itself and its wholly owned subsidiaries BofA Securities, Inc., a broker dealer registered under section 15 of the Act (15 U.S.C. 78o); Bank of America N.A., a bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); and Merrill Lynch International, a non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J).
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BANK OF AMERICA CORP /DE/

Signature:	/s/ Monica Yako
Name/Title:	Authorized Signatory
Date:	08/03/2026